Compare DLO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | VKTX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2021 | 2014 |
| Metric | DLO | VKTX |
|---|---|---|
| Price | $13.71 | $29.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $17.25 | ★ $95.86 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $26.98 | N/A |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.67 | $22.96 |
| 52 Week High | $16.78 | $43.15 |
| Indicator | DLO | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.58 | 33.86 |
| Support Level | $13.58 | $23.08 |
| Resistance Level | $13.99 | $35.85 |
| Average True Range (ATR) | 0.44 | 1.56 |
| MACD | 0.01 | -0.53 |
| Stochastic Oscillator | 67.05 | 12.67 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.